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Structural Studies of Salmonella typhimurium ArnB
(PmrH) Aminotransferase: A 4-Amino-4-Deoxy-
L-Arabinose Lipopolysaccharide-Modifying Enzyme
thought to confer resistance to AP by neutralizing the
charge of the LPS, thereby decreasing electrostatic at-
traction of cationic AP to the surface of the bacterium.
Resistance to AP in the pathogenic bacterium S. typhi-
murium is conferred by transcriptional activation of the
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Ketan S. Gajiwala, and Sean G. Buchanan pmrE/udg locus, which encodes UDP-glucose dehydro-
genase, plus a seven-gene operon pmrHFIJKLM [5].Structural Genomix
San Diego, California 92121 Bioinformatic analyses of these genes led to two inde-
pendent proposals for lipid A modification with L-Ara4N
[6, 7]. The pathway leading to L-Ara4N modification of
lipid A was described in recent publications from RaetzSummary
and coworkers [8–11].
ArnB (formerly PmrH) is encoded by the first openLipid A modification with 4-amino-4-deoxy-L-arabi-
nose confers on certain pathogenic bacteria, such as reading frame of the pmrHFIJKLM operon [5, 10]. This
enzyme catalyzes amino group transfer from glutamicSalmonella, resistance to cationic antimicrobial pep-
tides, including those derived from the innate immune acid to the C-4″ position of uridine 5-(-L-threo-penta-
pyranosyl-4″-ulose diphosphate; UDP-L-Ara4O), yield-system. ArnB catalysis of amino group transfer from
glutamic acid to the 4″-position of a UDP-linked keto- ing UDP-L-Ara4N and -ketoglutarate (Figure 1C) [8].
Orthologs of ArnB from three organisms known to mod-pyranose molecule to form UDP-4-amino-4-deoxy-L-
arabinose represents a key step in the lipid A modifica- ify lipid A with L-Ara4N (Escherichia coli K12, Yersinia
pestis, and Pseudomonas aeruginosa) are highly con-tion pathway. Structural and functional studies of the
ArnB aminotransferase were undertaken by combin- served (Figure 2). S. typhimurium, Y. pestis, and P. aeru-
ginosa are human pathogens causing gastroenteritis,ing X-ray crystallography with biochemical analyses.
High-resolution crystal structures were solved for two plague, and airway infections associated with cystic
fibrosis, respectively. The major cause of mortality innative forms and one covalently inhibited form of S.
typhimurium ArnB. These structures permitted identi- cystic fibrosis patients is inflammation of the airway
resulting from chronic P. aeruginosa infection [12]. Iso-fication of key residues involved in substrate binding
and catalysis, including a rarely observed nonprolyl lates of P. aeruginosa from the lungs of cystic fibrosis
patients possess L-Ara4N lipid A modifications associ-cis peptide bond in the active site.
ated with AP resistance and an increased inflammatory
response [13]. Enzymes in the pathway leading toIntroduction
L-Ara4N modification of lipid A may, therefore, represent
attractive targets for the development of antimicrobialLipopolysaccharide (LPS) is the major lipid species in
the outer leaflet of the outer membranes of Gram-nega- compounds.
Here, we describe the first high-resolution crystaltive bacteria. LPS is composed of a polysaccharide por-
tion, consisting of an O-specific antigen region and a structures of an L-Ara4N lipid A modification pathway-
specific enzyme. Structural and biochemical analysescore region, which is covalently attached to a molecule
of lipid A (Figures 1A and 1B). Lipid A anchors LPS in provide insights into ArnB function at the molecular
level, and allow us to propose a mechanism of enzymethe outer membrane, presenting the polysaccharide to
the external environment. Some Gram-negative bacteria action. We suggest that ArnB aminotransferase repre-
sents a promising target for development of antibacte-have developed defense mechanisms, including cova-
lent lipid A modifications, to neutralize antimicrobial rial agents, which may be accelerated by structure-
based drug design.compounds found within various environmental niches.
Lipid A elicits expression of various antimicrobial factors
by the host immune system, such as cytokines, chemo- Results and Discussion
kines, and cationic antimicrobial peptides (AP) [1, 2].
APs are components of the innate immune system, and Architecture of ArnB
ArnB adopts a type 1 aminotransferase fold (Figure 3A),are believed to kill bacteria by disrupting membrane
integrity. S. typhimurium resists the effects of AP via of which aspartate aminotransferase (AAT) represents
the archetype [14]. Like other structures of the type 1PhoP-PhoQ-dependent modifications of lipid A [3, 4].
One such modification is covalent attachment of aminotransferase fold family, ArnB is homodimeric (data
not shown), with approximate dimensions of 40 A˚ 4-amino-4-deoxy-L-arabinose (L-Ara4N) to lipid A,
which is further regulated by the PmrA-PmrB two-com- 50 A˚  90 A˚. The large N-terminal cofactor binding do-
main consists of a central seven-stranded, mixed polar-ponent system (Figure 1B) [3, 4]. Aminoarabinose is
ity  sheet (strand order 1, 9, 8, 5, 4, 2, 3;
Figures 2 and 3A). helices1–7 plus residues 246–2601Correspondence: brian_noland@stromix.com
2 Present address: Department of Molecular, Cellular, and Develop-
mental Biology, University of California, Santa Barbara, California Key words: aminoarabinose; aminotransferase; cis peptide; lipo-
polysaccharide; lipid A; PLP93106.
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Figure 1. Lipopolysaccharide Structure Showing Modification with 4-Amino-4-Deoxy-L-Arabinose
(A) Schematic drawing of lipopolysaccharide from Gram-negative bacteria.
(B) The structure of lipid A from S. typhimurium modified at the 1- and 4-phosphate positions with 4-amino-4-deoxy-L-arabinose. The
1-phosphate position can also be substituted with phosphoethanolamine instead of L-Ara4N in S. typhimurium [3, 6].
(C) Enzyme reaction catalyzed by the ArnB aminotransferase.
of helix 8 pack around the central  sheet of the asymmetric unit, with the second half of the dimer re-
lated by crystallographic 2-fold symmetry (Figure 3A).N-terminal domain. The smaller C-terminal domain con-
sists of an antiparallel, three-stranded  sheet (12, 15, An extensive dimer interface buries more than 2500 A˚2
of solvent-accessible surface area per monomer. A DALI14) plus  helices 8 (residues 261–275) and 9–14.
Two small antiparallel  sheet excursions, 10-11 and [37] server search of the Protein Data Bank (PDB; http://
www.rcsb.org/pdb/) identified 3-amino-5-hydroxyben-7-6-13, pack against the N-terminal domain. All of
our ArnB crystal structures have one protomer per zoic acid (AHBA) synthase from Amycolatopsis mediter-
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Figure 2. Sequence Alignment of ArnB from S. typhimurium with Orthologs from E. coli K12, Y. pestis, and P. aeruginosa
The secondary structure from the Salmonella enzyme is shown above the alignment. Identities are indicated by the filled red boxes. Sequence
identities for E. coli K12, Y. pestis, and P. aeruginosa ArnB with S. typhimurium ArnB are 82%, 69%, and 61%, respectively.
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ranei [15] as the closest structural homolog of ArnB class, because the spectroscopic signal of the pyridoxal
chromophore is exquisitely sensitive to changes in(rmsd of 2.3 A˚ for 351 equivalent -carbons; 28%
identity). chemical environment [18]. The absorbance spectrum
of our purified ArnB preparations suggested that the
cofactor was largely in the aminated, or pyridoxaminePyridoxal Cofactor Binding Site
5-phosphate (PMP), form (maximum centered at 340The active sites of type 1 aminotransferases are com-
nm; Figure 4A). This spectroscopic inference was con-posed of residues from both halves of the dimer [14].
firmed by our ArnB crystal structure (Figure 5A; TableThe location of the ArnB active site is unambiguously
1). An electron density feature extends from the C4identified by the location of the pyridoxal cofactor (Fig-
position of the cofactor into which an amino group couldure 3B), which interacts with several conserved resi-
be modeled, and Lys188 was found in a retracted posi-dues. The phosphate moiety of the cofactor is stabilized
tion that is not compatible with the internal aldimineby the macrodipole of  helix 3, and phosphate oxy-
(Figure 5A). PLP-dependent aminotransferases catalyzegens are hydrogen bonded to the hydroxyl groups of
transfer of an amino group between an amino acid andThr64 and Ser183. The phosphate group is also bound
an amino acceptor substrate, usually an oxoacid [14].to Glu194, via an ordered water bridge. The side chain
Transfer occurs through two half-reactions, where theof His185 interacts with the carboxylate of Glu194, and
aminated form of the holoenzyme, the E·PMP enzymethe side chain of Trp89 makes direct contact with the
form, results from the first half-reaction. Our structuralpyridine ring of the cofactor. The indole group is oriented
and biochemical data document that ArnB exists in a60 from parallel ring stacking, and appears to dictate
stable noncovalent E·PMP intermediate state in the ab-the approach of substrates to the C4 position of the
sence of an amino acceptor substrate.cofactor. The imidazole moiety of His163 forms a salt
bridge with the 3-oxygen of the cofactor, suggesting
that His163 helps to maintain the negative charge at this ArnB Internal Aldimine (E-PLP) Form
oxygen. A deprotonated 3-oxygen may be necessary to Addition of -ketoglutarate, the product of the first half-
stabilize the protonated internal aldimine and proposed reaction, to E·PMP ArnB reduced the observed PMP
ketimine intermediate. The carboxylate group of Asp160 absorbance peak at 340 nm and produced a concomi-
makes a salt bridge with the pyridine nitrogen to stabilize tant increase in absorbance at 430 nm, which is consis-
the protonated form of this atom, thereby enhancing the tent with conversion to the internal aldimine or E-PLP
electron sink properties of the cofactor. form (Figure 4A). Electrospray ionization mass spec-
The peptide bond between His329 and Phe330 adopts trometry of NaBH4-reduced/-ketoglutarate-treated en-
the cis conformation (Figure 3C). When nonprolyl cis zyme showed two species, one corresponding to native
peptide bonds are observed in protein structures, they ArnB, and another 229  4 mass units heavier, corre-
usually occur in functionally important regions of the sponding to the covalent E-PLP adduct (data not
polypeptide chain [16]. To the best of our knowledge, shown). Untreated protein showed only the mass corre-
our structures provide the first example of a nonprolyl sponding to the native enzyme (data not shown). A sec-
cis peptide bond among the type 1 aminotransferases. ond crystal structure of ArnB grown in the presence of
Nonprolyl cis peptide bonds are rare, presumably be- -ketoglutarate was determined at 1.96 A˚ resolution by
cause they are destabilizing (model compound studies molecular replacement (Figure 5B; Table 1), revealing
suggest energetic penalties of about 5 kcal/mol) [17]. the expected Schiff base between the -amino group of
The His-Phe combination at this position in ArnB is Lys188 and C4 of the cofactor.
strictly conserved among bacteria known to modify lipid The -amino group of Lys188 lies out of the plane
A with L-Ara4N (Figure 2), and we believe that the cis defined by the pyridoxal ring of the cofactor, thus deviat-
conformation also exists in these orthologous enzymes. ing from ideal geometry. However, the internal aldimine
The cis peptide bond is stabilized by a hydrogen bond is expected to be stabilized in its protonated form by
between the phenolic oxygen of Tyr136 and the back- the anionic form of the 3-oxygen, because the distance
bone carbonyl oxygen of His329 (distance  2.7 A˚; Fig- between these atoms is 2.6 A˚. A bound molecule of
ures 3B and 3C). The role of the nonprolyl cis peptide -ketoglutarate was also observed in this structure, and
bond in the ArnB active site is unclear at present. was modeled at 50% occupancy. In E·PMP ArnB, resi-
dues 219–233 are disordered. Binding of-ketoglutarate
in E-PLP ArnB stabilizes the structure of this loop, per-Pyridoxamine 5-Phosphate (PMP) Form of ArnB
Pyridoxal cofactors represent convenient spectro- mitting ready visualization of residues 229–232 in the
electron density map. Arg229, from the symmetry-scopic probes for measuring the activity of this enzyme
Figure 3. Architecture of ArnB Aminotransferase
(A) Stereo diagram of the ArnB dimer. The -carbon backbone is rendered to show secondary structure and the protomers are colored
individually. In one protomer, the N-terminal cofactor binding domain is colored blue and the smaller C-terminal domain is colored yellow.
The PMP cofactors are shown in space-filling representation.
(B) The cofactor binding site. The cofactor and conserved residues important for binding and catalysis are shown in stick representation.
Interactions are indicated with dotted lines.
(C) Stereo drawing of the electron density map in the region of the nonprolyl cis peptide bond between residues His329 and Phe330, with
the phenolic side chain of Tyr136 forming a hydrogen bond with the backbone carbonyl oxygen of Phe330. The experimentally determined
SeMet MAD electron density map is shown at the 1	 contour level.
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Figure 4. ArnB Absorbance Spectroscopy
(A) Absorbance spectra for ArnB in the E·PMP (thick line), E-PLP (thin line), and the E·PLP-cycloserine (dotted line) forms. The arrow indicates
the observed isosbestic point at 363 nm.
(B) Kinetics of aminotransfer from L-methionine to E-PLP ArnB measured at 340 nm () and 430 nm () (enzyme concentration  23 
M,
L-methionine concentration  20 mM). The fitted curves (Equation 1) give observed rate constants 0.065  0.014 min1 and 0.051  0.013
min1 for data obtained at 340 nm and 430 nm, respectively.
related protomer, appears to bind the -carboxylate indicated by the loss of the 430 nm internal aldimine
peak in the cofactor absorbance spectrum and the ap-group of -ketoglutarate, and we suggest that this resi-
pearance of a peak centered at 334 nm (Figure 4A). Adue makes up half of the L-glutamate substrate selectiv-
third structure of L-cycloserine-inhibited ArnB (E·PLP-ity filter discussed below. With the exception of the
cycloser) was determined at 2.07 A˚ resolution (Figureordering of the 229–232 loop, no large-scale re-
5C; Table 1). The electron density map for E·PLP-arrangements between the E·PMP and E-PLP ArnB
cycloser ArnB shows the formation of a PLP-cycloserinestructures were observed.
adduct, and the loss of the internal aldimine betweenExcess methionine in the purification buffers may ex-
cofactor and Lys188 (Figure 5C). Active site residues doplain why the ArnB was initially isolated in the aminated
not show large-scale movements to accommodate theor E·PMP enzyme form. The enzyme was readily con-
inhibitor, but the cofactor does tilt back to roughly theverted from the E-PLP form back to the E·PMP form, in
same orientation as observed in the E·PMP structurethe presence of excess L-methionine (Figure 4B). The
(16). For reference, the cofactor tilts by 27 betweenD-isomer of methionine had no such effect (data not
the internal aldimine- and the gabaculine-inhibitedshown). Conversion kinetics were monitored by measur-
forms of ornithine aminotransferase [21]. Larger cofac-ing the decrease in absorbance at 430 nm and the con-
tor tilt angles in the ArnB aminotransferase appear un-comitant increase in absorbance at 340 nm as a function
likely because of the orientation of the indole groupof time (Figure 4B). Coupling of these two spectroscopic
of Trp89 (Figure 3B). In dialkylglycine decarboxylasechanges was evident from the nearly equivalent ob-
(DGD), Trp138 is believed to restrict the tilting of theserved rate constants, and the clear isosbestic point at
PLP cofactor in a similar manner [20]. The cofactor tilt363 nm (Figure 4). The L-isomer of aspartic acid was
angle between the internal aldimine- and the 1-aminocy-also able to act as an amino donor, albeit at a slower
clopropane-1-carboxylate-inhibited forms of DGD israte than L-methionine (data not shown). L-glutamate
13 [20].was the fastest L-amino acid tested, exceeding the limi-
The -carbon of cycloserine has apparent sp2 hybrid-tations of our manual mixing studies (data not shown).
ization, consistent with abstraction of the L-cycloserineThe natural amino donor substrate of ArnB has yet to
-proton, presumably after initial formation of the exter-be unambiguously identified, but it has been suggested
nal aldimine (Figure 5C). Lys188 may act as a generalthat L-glutamate is the most likely candidate [8]. Type
base to abstract the -proton, and we propose that it1 aminotransferases use a specific substrate/product
plays a role as a general acid or base in several steps inpair and often use L-glutamate/-ketoglutarate as a sec-
the enzymatic mechanism. The sp2-hybridized -carbonond pair [14]. Breazeale et al. have observed that ArnB
makes cycloserine nearly planar in the PLP adduct (Fig-from E. coli K12 can use L-glutamine as an amino donor
ure 5C). We suggest that the PLP-cycloserine adductsubstrate, but does so less efficiently than with L-gluta-
represents the resonance-stabilized structure shown inmate [8].
Figure 5C. In the original mechanism proposed for
cycloserine inhibition of PLP-dependent enzymes, the
L-Cycloserine Inhibition of ArnB ketimine intermediate species is attacked by an enzyme
Cycloserine is a nonstandard amino acid, and both L- nucleophile, causing the cycloserine ring to open, yield-
and D-isomer-inhibited PLP enzyme structures have ing a covalent enzyme adduct [22]. Our E·PLP-cycloser
been described [19, 20]. ArnB in the E·PMP form did ArnB structure documents that the PLP-cycloserine ad-
not react with L-cycloserine, but E-PLP ArnB was rapidly duct is bound to the enzyme via noncovalent interac-
tions.inactivated in the presence of excess L-cycloserine, as
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Figure 5. ArnB Active Site Electron Density
Maps
(A) E·PMP ArnB.
(B) E-PLP ArnB.
(C) E·PLP-cycloserine ArnB. The proposed
chemical structure of the pyridoxal cofactor
is shown to the immediate right of each omit
electron density map (contoured at 3.0	). All
nonprotein atoms were removed from the
model as well as the atoms from Lys188 for
the calculation of the omit density maps.
Two other cycloserine-inhibited PLP-dependent en- allowed us to understand how ArnB discriminates
among various -ketoacids as substrates by runningzyme structures have been described [19, 20]. D-cyclo-
serine-inhibited D-amino acid aminotransferase (D-aAT) the first half-reaction in reverse (Figure 6). The side chain
of Lys241 from the opposite subunit binds the terminalshares the resonance-stabilized inhibited form seen in
E·PLP-cycloser ArnB [19]. High-resolution crystal struc- carboxylate group of -ketoglutarate (Figure 6B). The
guanido group of Arg229, again from the opposite sub-tures of both D- and L-cycloserine-inhibited DGD have
been described [20]. The L-cycloserine-inhibited form unit, binds the -carboxylate group of -ketoglutarate.
Together, Lys241 and Arg229 appear to constitute ais planar at the -carbon, consistent with a resonance-
stabilized structure similar to those observed in D-aAT selectivity filter for -ketoglutarate, and presumably the
L-glutamate substrate. The rate of conversion betweenand ArnB. The D-cycloserine-inhibited form of DGD is
tetrahedral at the -carbon, because the -proton is not the E·PMP and E-PLP enzyme forms was followed by
monitoring absorbance increase at 430 nm as a functionpresented to the active site lysine for abstraction [20].
of time, using various -ketoacids as amino acceptor
substrates (Figure 6A). There are two methylenes be--Ketoacids Serve as Amino Acceptor Substrates
ArnB shows some promiscuity with respect to the tween the ketone and the terminal carboxylate group
in -ketoglutarate (Figure 6A). Oxaloacetate, which ischoice of -ketoacids that serve as amino acceptor sub-
strates. The presence of bound -ketoglutarate product shorter by one methylene group, shows a 250-fold re-
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Table 1. Data Collection and Refinement Statistics
E•PMP* E-PLP E•PLP-cycloserine
Crystal
Wavelength (A˚) 0.9795 0.9795 0.9795
Space group P43212 P43212 P43212
Cell dimensions (A˚) 91.2, 128.6 91.2, 128.7 90.9, 127.7
Resolution (A˚) 29.6–1.70 45.6–1.96 38.6–2.08
Observations 827,017 537,578 440,660
Unique reflections 60,130 39,164 33,311
Completeness (%) 99.9 (99.9) 99.2 (94.9) 99.4 (96.3)
Redundancy 13.7 (13.2) 13.7 (9.3) 13.2 (8.6)
I/	(I) 15.6 (1.9) 13.1 (3.3) 11.6 (2.4)
Rsym(I) 0.127 (1.609) 0.153 (0.805) 0.200 (1.419)
Refinement
Reflections used 60,130 39,164 33,311
R factor for all reflections 0.217 0.207 0.223
Number of reflections above 57,454 36,413 30,476
2	(F) and resolution from 5.0 A˚,
high-resolution limit
Rwork 0.210 0.198 0.212
Rfree (5% of data) 0.253 0.241 0.250
B factor for all atoms (A˚2) 29.4 25.7 31.5
Model
Total number of atoms 3,248 3,256 3,017
Protein residues 366 370 366
Water molecules 477 442 254
Ligand molecules 1 PMP 1 PLP 1 PLP
1 -ketoglutarate (50%) 1 PLP-cycloserine
2 glycerol
Structure validation
Phi-psi core region (%) 91.5 89.9 90.2
Residues in disallowed regions 1 1 1
Rmsd from ideal bond length 0.012 0.011 0.011
Rmsd from ideal bond angle 1.78 1.76 2.02
Values in parentheses refer to the highest resolution shell. All R factors were calculated with SFCHECK [34].
*Data for the E·PMP structure were obtained from SeMet protein. Validation statistics were calculated with PROCHECK [32].
duction in aminotransfer rate from that of -ketogluta- ArnB utilization of L-glutamate as the amino donor sub-
strate.rate. -ketoadipate, which is longer by one methylene
group, shows a mere 3-fold reduction in aminotransfer
rate with respect to -ketoglutarate. Shortening the dis- Proposed Enzymatic Mechanism
With knowledge of the substrates, products, and thetance between the -keto group and the terminal car-
boxylate group would be expected to decrease interac- identification of key active site residues, we can propose
an enzymatic mechanism for ArnB, which is similar totion of the carboxylate with Lys241 (Figure 6B). The
large observed decrease in aminotransfer rate between the proposed mechanism for aspartate aminotransfer-
ase [23]. In the first step of the reaction, E-PLP ArnBoxaloacetate and -ketoglutarate may be due to electro-
static repulsion of the terminal carboxylate group of binds L-glutamate, and the internal aldimine is attacked
by the -amino group of L-glutamate to generate theoxaloacetate and both the phosphate oxygen and the
carboxylate side chain of Glu194. Increasing the dis- external aldimine (Figure 7A). Presumably, the electron
sink properties of the PLP render the glutamate-protontance between the -keto group and the terminal car-
boxylate group (as in -ketoadipate) does not appear labile to abstraction. Lys188 serves as a general base
and abstracts the -proton from the external aldimine,to compromise interaction of the terminal carboxylate
(model building results not shown), which may explain giving a quinoid intermediate species. The quinoid inter-
mediate then accepts a proton from Lys188 on the sithe small observed aminotransfer rate decrease. Indi-
rect evidence that electrostatic repulsion causes the face of the cofactor to reduce the C4 position of the
cofactor to generate the ketimine intermediate. Hydroly-observed reduction in aminotransfer rate between oxa-
loacetate and -ketoglutarate was provided by studies sis of the ketimine produces the E·PMP enzyme form
and the first product, -ketoglutarate. Figure 7B illus-of pyruvate (the product of terminal carboxylate removal
from oxaloacetate), which showed an 4-fold increase trates the next four steps in the second half-reaction.
The E·PMP enzyme form binds a molecule of UDP-L-in aminotransferase activity (Figure 6A). Our findings
suggest that ArnB prefers dicarboxylic acid substrates Ara4O, and the amino group of PMP attacks the 4″-keto
position of the ketoarabinose moiety to produce waterwith at least two methylenes between the -carbon and
the terminal carboxylate group, which is consistent with and the corresponding ketimine intermediate. Lys188
Structural Studies of ArnB from S. typhimurium
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Figure 6. ArnB Aminotransfer Kinetics
(A) The apparent first order rate constants for
aminotransfer from E·PMP ArnB to pyruvate,
oxaloacetate, -ketoglutarate, and -keto-
adipate, shown on a logarithmic rate scale
with compound structures above the bar and
error bars (standard deviation from three or
four independent measurements). The num-
ber of methylenes between the -carbon and
the terminal carboxylate group are also indi-
cated.
(B) The -ketoglutarate binding site from the
E-PLP ArnB crystal structure. The -ketoglu-
tarate ligand, PLP, and the selected residues
are modeled as stick figures (C, white or yel-
low for second protomer; O, red; N, blue).
Electrostatic interactions are denoted with
dotted lines.
then abstracts the pro-S proton from the C4 position kill bacteria by disrupting membrane integrity. Patho-
genic Gram-negative bacteria such as S. typhimuriumof the cofactor to generate a quinoid intermediate. Re-
arrangement of the quinoid species causes the 4″-car- modify their LPS in several distinct ways to evade the
innate host immune system and abrogate the effective-bon of the arabinose sugar moiety to accept a proton
from Lys188, generating the external aldimine. In the ness of cationic antimicrobial peptides [38]. One such
modification is addition of aminoarabinose to the phos-final step, Lys188 attacks the C4 position of the external
aldimine in a transaldimination reaction to give the sec- phate groups of lipid A. Aminoarabinose neutralizes the
negative charge of lipid A, decreasing the electrostaticond product, UDP-4-amino-4-deoxy-L-arabinose, and
the regenerated E-PLP form of the enzyme. interaction between cationic antimicrobial peptides and
the bacterial cell surface. Bacterial resistance to the
innate immune system is essential for virulence [38].Biological Implications
Blockade of these resistance mechanisms may, there-
fore, represent an attractive target for novel antibioticLPS is the most abundant macromolecule on the surface
of Gram-negative bacteria and is an endotoxin that elic- therapies.
Polymyxins are cyclic cationic antimicrobial peptidesits immune responses from the infected host. One of
the ways that the immune system responds to infection used clinically as aerosols to treat Pseudomonas aerugi-
nosa infections in cystic fibrosis patients [39–41]. P.is by producing cationic antimicrobial peptides, which
Structure
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Figure 7. Proposed ArnB Enzyme Mechanism
(A) The first half-reaction.
(B) The second half-reaction. The lysine residue is Lys188.
aeruginosa isolated from the lungs of cystic fibrosis A biosynthesis could potentially be utilized in the treat-
ment of polymyxin-resistant P. aeruginosa as well aspatients have been shown to contain aminoarabinose-
modified lipid A [13]. Inhibitors of aminoarabinose lipid other polymyxin-resistant organisms.
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lar graphics images were created with SPOCK [36] unless otherwiseArnB aminotransferase is a key enzyme in the biosyn-
indicated.thetic pathway that leads to aminoarabinose-modified
LPS. High-resolution structures of ArnB from S. typhi-
Mass Spectrometry
murium described in this paper provide for an under- E-PLP form ArnB samples were prepared by treating 230
M enzyme
standing of the enzyme at the molecular level and pro- with 2.5 mM -ketoglutaric acid for 30 min on ice. The resulting
vide the means for rational inhibitor design. Each of the Schiff base between the active site lysine and the cofactor was
reduced by treatment with 100 mM NaBH4 for 30 min on ice. Athree structures presented captures ArnB at a different
control sample of the enzyme in the E·PMP form, untreated withstage of catalysis, showing how the enzyme interacts
-ketoglutaric acid, was also reduced in an identical manner. Fol-with its cofactor, a product, and an inhibitor. In addition,
lowing NaBH4 reduction, the samples were thrice dialyzed againstthe structures reveal a rarely observed structural fea- a 1000-fold excess (v/v) of 3 mM Tris-Cl (pH 8). Mass spectra were
ture, a nonprolyl cis peptide bond, in the active site acquired in positive ion mode with an API-150EX single quadruple
of ArnB. Our structures, and the proposed enzymatic mass spectrometer (PE Sciex). Samples were diluted in 50% metha-
nol-water, and5% acetic acid was added to aid protonation. Sam-mechanism, should serve as a starting point for struc-
ples were introduced into the mass spectrometer at a flow rate ofture-based antimicrobial compound design efforts.
5 
l/min, with ion spray voltage  5000 V, and orifice potential 
50 V.
Experimental Procedures
ArnB Aminotransfer Assays
Protein Expression and Purification Aminotransfer half-reactions were measured at an enzyme concen-
The gene encoding S. typhimurium ArnB was amplified from geno- tration of 23 
M and substrates were added to a final concentration
mic DNA obtained from the ATCC by conventional PCR and then of 250 
M, unless otherwise indicated. Reaction progress was fol-
subcloned into a pET26b-derived vector, which adds a C-terminal lowed by monitoring the absorbance maxima of the PMP or PLP
GSHHHHHH tag. BL21(DE3) cells transformed with the resulting cofactor forms at 340 nm or 430 nm, respectively. Resulting time
plasmid were grown in LB media, and induced with 1 mM IPTG courses were fit to Equation 1, describing a single-exponential de-
overnight at 20C to express the desired fusion protein. SeMet pro- cay,
tein was produced using the same cells, following the method de-
Yobs  ((Y0  Y∞)ekt)  Y∞, (1)scribed by Doublie´ [24]. Cells were harvested by centrifugation,
lysed by sonication, and the fusion protein was purified by nickel
where Yobs  observed signal, Y0  signal at time zero, Y∞  signalaffinity chromatography (Ni HiTrap column; AP Biotech) followed by
at infinite time, k is the apparent first order rate constant, and t is
gel filtration (Superdex 75; AP Biotech).
time. Nonlinear least squares fits were performed with Kaleidagraph
v3.51 (Synergy Software).
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